Description

Lenvanix (Lenvatinib) 10mg capsules are used to treat various types of cancer, including differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.The key points about Lenvanix (Lenvatinib) 10mg capsules are:

• Indication: Lenvatinib is a tyrosine kinase inhibitor used to treat locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC), in combination with everolimus for advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy, and for first-line treatment of unresectable hepatocellular carcinoma (HCC).
• Dosage: The recommended dose for DTC is 24mg (two 10mg capsules and one 4mg capsule) taken orally once daily. For RCC in combination with everolimus, the dose is 18mg (one 10mg capsule and two 4mg capsules) taken orally once daily. For HCC, the dose is based on body weight – <60kg is 8mg once daily, ≥60kg is 12mg once daily.
• Side Effects: Common side effects include hypertension, diarrhea, fatigue, nausea, decreased appetite, and liver/kidney dysfunction. Serious side effects can include cardiovascular issues, gastrointestinal perforation, and thromboembolic events.
• Monitoring: Liver function, blood pressure, and kidney function need to be regularly monitored during treatment with Lenvanix.
  

  Indication

  Lenvatinib is a tyrosine kinase inhibitor used to treat the following types of cancer:

  • Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)
  • Advanced renal cell carcinoma (RCC) in combination with everolimus, following one prior anti-angiogenic therapy
  • Unresectable hepatocellular carcinoma (HCC) as first-line treatment

  Dosage

  • For DTC, the recommended dose is 24mg (two 10mg capsules and one 4mg capsule) taken orally once daily.
  • For RCC in combination with everolimus, the dose is 18mg (one 10mg capsule and two 4mg capsules) taken orally once daily.
  • For HCC, the dose is based on body weight:
    • <60kg: 8mg once daily
    • ≥60kg: 12mg once daily

  Side Effects

  Common side effects include:

  • Hypertension
  • Diarrhea
  • Fatigue
  • Nausea
  • Decreased appetite
  • Liver/kidney dysfunction

  Serious side effects can include:

  • Cardiovascular issues
  • Gastrointestinal perforation
  • Thromboembolic events

  Monitoring

  Patients taking Lenvanix (Lenvatinib) 10mg capsules require regular monitoring of:

  • Liver function
  • Blood pressure
  • Kidney function
    

    Key Benefits

    • Treats various types of cancer, including:
      • Differentiated thyroid cancer (DTC)
      • Advanced renal cell carcinoma (RCC) in combination with everolimus
      • Unresectable hepatocellular carcinoma (HCC) as first-line treatment
    • Works as a tyrosine kinase inhibitor, blocking signals that promote cancer cell growth

    Key Ingredients

    • Active Ingredient: Lenvatinib (as the mesylate salt)
    • Formulation: 10mg capsules
    • Other Ingredients: The specific inactive ingredients are not provided in the search results.
    

    Lenvatinib

    Anti-cancer medication

    More

    Brand name

    Lenvima

    Developer

    Eisai Co.

    Primary use

    Treatment of certain kinds of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma

    Mechanism of Action

    Lenvatinib is a multiple receptor tyrosine kinase (RTK) inhibitor that blocks the activities of several growth factor receptors implicated in tumor growth and angiogenesis:

    • Vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3)
    • Fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, FGFR4)
    • Platelet-derived growth factor receptor alpha (PDGFRα)
    • RET proto-oncogene
    • KIT proto-oncogene

    By inhibiting these receptors, lenvatinib disrupts the signaling pathways that promote tumor angiogenesis, growth and progression. VEGFR2 inhibition is thought to be the main mechanism behind the common side effect of hypertension.Lenvatinib binds to the ATP binding site of VEGFR2 and an adjacent region via a cyclopropane ring, thereby inhibiting tyrosine kinase activity and associated signaling pathways. It is absorbed quickly, reaching peak plasma levels in 1-4 hours, with an estimated 85% bioavailability.

    Efficacy in Metastatic/Radioiodine-Refractory Thyroid Cancer

    • In a real-world study, Lenvatinib demonstrated a disease control rate of 85.2% and a median progression-free survival (PFS) of 12 months in patients with advanced differentiated thyroid cancer (DTC) .
    • A systematic review and meta-analysis found that Lenvatinib was associated with significantly prolonged PFS (HR 0.24) and overall survival (HR 0.65) compared to placebo in patients with radioiodine-refractory thyroid carcinoma .
    • In a study of patients with poorly differentiated thyroid cancer (PDTC), Lenvatinib showed a 100% disease control rate, with a median PFS of 12 months and median overall survival not yet reached .
    • An observational study in Japan across all thyroid cancer subtypes (DTC, medullary, anaplastic) found Lenvatinib had meaningful antitumor activity, with overall response rates of 59.2% in DTC, 45.0% in medullary, and 43.8% in anaplastic .

    Dosage

    The recommended dosage of Lenvanix (Lenvatinib) 10mg capsules for the treatment of various cancers is:Differentiated Thyroid Cancer (DTC):

    • 24mg (two 10mg capsules and one 4mg capsule) taken orally once daily

    Renal Cell Carcinoma (RCC):

    • In combination with everolimus: 18mg (one 10mg capsule and two 4mg capsules) taken orally once daily
    • In combination with pembrolizumab: 20mg taken orally once daily

    Hepatocellular Carcinoma (HCC):

    • <60kg body weight: 8mg (two 4mg capsules) taken orally once daily
    • ≥60kg body weight: 12mg (three 4mg capsules) taken orally once daily

    Dosage should be modified as needed based on tolerability and adverse reactions.

    Storage

    Lenvanix (Lenvatinib) 10mg capsules should be stored at room temperature between 68-77°F (20-25°C). Protect from moisture.

    Reviews

    The search results do not provide any direct reviews or feedback on the efficacy or tolerability of Lenvanix (Lenvatinib) 10mg capsules. However, the information on the approved indications, dosing, and administration suggests that this medication is an important treatment option for patients with advanced, progressive, or unresectable thyroid, renal, and liver cancers. The detailed dosing guidelines and monitoring recommendations indicate this is a complex medication that requires careful management by healthcare providers.